VNK-101

Allogeneic NK Cell Cancer Immunotherapy

Leveraging the power of its VY-UC allogeneic engineering platform, Vycellix is advancing VNK-101 as first-in-class, off-the-shelf NK cell cancer immunotherapy.  The Company is preparing to launch a Phase 1 clinical trial for the treatment of multiple myeloma blood cancer: